The FDA approved nipocalimab (Imaavy) injection to treat adults and children ages 12 and older with generalized myasthenia ...

Immune cells called macrophages, which guard the entry point to the lymph nodes, handcuff these invaders and take them to ...

The FDA has approved a monoclonal antibody to treat individuals aged 12 years and older with generalized myasthenia gravis ...

This valuable study provides insights into a key question in comparative neuroanatomy and development. The authors provide evidence of the role for a particular micro-RNA in regulating the development ...

Participants in the CLL11 trial and a smaller group of patients followed after study completion showed improved overall ...

BNT162b2 mRNA vaccination attenuates innate immune function in humans - ...

Nipocalimab-aahu is a human immunoglobulin G1 monoclonal antibody that binds with high affinity to the neonatal Fc receptor, resulting in the reduction of circulating IgG levels.

Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, ...

Discover groundbreaking research and presentations from leading companies at the ARVO 2025 Annual Meeting, advancing ...

House: Johnson & Johnson has received approval from the U.S. Food and Drug Administration (FDA) for IMAAVY (nipocalimab-aahu) ...

Mepolizumab significantly reduced the annualized rate of moderate or severe exacerbations in COPD with an eosinophilic ...

Aidixi plus BCG showed strong early efficacy and manageable safety in patients with high-risk, HER2-expressing ...